Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Subject: Schizophrenia - PUBLISHED VIA Brazilian Journal of Medical and Biological Research

Author(s):
Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS

Departamento de Neurologia, Psiquiatria e Psicologia Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. awzuardi@fmrp.usp.br

 View Source >>

Related Studies:

Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Published via Neuropsychopharmacology

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

Published via Drug Testing and Analysis

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Published via Current Pharmaceutical Design

Cannabidiol as a potential treatment for psychosis.

Published via European Neuropsychopharmacology

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Published via Translational Psychiatry

View all medical studies

Learn More About Cannabis

Website & branding by the Ganjapreneur in-house agency:

Blue Dream - Uplifted cannabis industry branding & marketing.

Uplifted cannabis industry branding & marketing.